175 related articles for article (PubMed ID: 36905578)
21. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials.
Manning-Bennett AT; Cervesi J; Bandinelli PA; Sorich MJ; Hopkins AM
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831064
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
24. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.
Badaoui S; Shahnam A; McKinnon RA; Abuhelwa AY; Sorich MJ; Hopkins AM
Transl Lung Cancer Res; 2022 Mar; 11(3):432-439. PubMed ID: 35399575
[TBL] [Abstract][Full Text] [Related]
25. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K; Shimokawa M; Mizuki F; Takamori S; Takenaka T; Miura N; Shikada Y; Yoshizumi T
Eur J Med Res; 2022 Aug; 27(1):157. PubMed ID: 35999618
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
[TBL] [Abstract][Full Text] [Related]
27. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O; Mori K; Takata S; Shibata K; Chikamori K; Kimura N; Nagai Y; Nakagawa T; Igawa S; Harada T; Yoshioka H; Tanaka H; Nogawa H; Satoh H; Shiozawa T; Tsuji K; Kobayashi K; Kaira K
Thorac Cancer; 2024 Jan; 15(2):163-171. PubMed ID: 38013668
[TBL] [Abstract][Full Text] [Related]
28. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
29. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
[TBL] [Abstract][Full Text] [Related]
31. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
32. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
[TBL] [Abstract][Full Text] [Related]
34. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
35. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
Roh J; Eom JS; Lee MK; Kim J; Jang T; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Kim MH
Am J Clin Oncol; 2021 Jul; 44(7):356-360. PubMed ID: 34014843
[TBL] [Abstract][Full Text] [Related]
37. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
39. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
